Can-Fite BioPharma Ltd.

Can-Fite Presents Final Positive Data from Phase IIa Pancreatic Cancer Study of Namodenoson at ESMO 2026

Can-Fite presented final Phase IIa data for namodenoson in advanced pancreatic ductal adenocarcinoma at the ESMO 2026 Congress, with the primary safety endpoint achieved and only mild-to-moderate treatment-related adverse events across 20 enrolled patients. Exploratory analyses showed median overall survival of 6.28 months in third-line patients surviving beyond two months, and one second-line patient achieved 16.39 months progression-free survival and over 20.7 months overall survival. The company cautions the survival findings are hypothesis-generating given the open-label design, absence of a randomized comparator, and post hoc subgroup selection; namodenoson is also in a Phase 3 HCC trial and a Phase 2b MASH trial.

•6d ago

Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation

A peer-reviewed case report published in the Japanese Journal of Gastroenterology and Hepatology describes a patient with advanced decompensated liver cirrhosis whose ascites resolved and esophageal varices regressed during treatment with Can-Fite's Namodenoson, allowing discontinuation of diuretic therapy. After approximately 28 months of Namodenoson treatment the patient remained clinically stable and underwent successful orthotopic liver transplantation in January 2026, with favorable post-transplant recovery. Treating physician Prof. Ohad Etzion noted the improvements in portal hypertension complications occurred despite continued deterioration in underlying liver function, and while a single-patient observation, the findings support further evaluation of Namodenoson in advanced liver disease. Namodenoson is separately in a pivotal Phase 3 trial for hepatocellular carcinoma and a Phase 2b trial for MASH, while Can-Fite's lead candidate Piclidenoson is in a pivotal Phase III psoriasis study.

•1mo ago

Can-Fite: Namodenoson Enhances the Anti-Cancer Effect of Chemotherapy in Pancreatic Cancer

Can-Fite reported preclinical data showing namodenoson enhances the anti-cancer effect of gemcitabine in pancreatic cancer by increasing apoptosis. The findings provide mechanistic support for the design of the company's planned Phase IIb study combining namodenoson with gemcitabine and Nab-paclitaxel. Separately, clinical results from the Phase 2a pancreatic cancer study have been accepted for presentation at the ESMO Congress 2026.

•2mo ago

Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates

Can-Fite provided an update on the regulatory status of its lead candidates, Namodenoson and Piclidenoson, confirming their advancement in Phase III programs under FDA and EMA frameworks. Namodenoson holds FDA Fast Track and U.S. and European Orphan Drug designations for its pivotal Phase III study in advanced liver cancer (HCC) with underlying liver cirrhosis. Piclidenoson is progressing through Phase III development for the treatment of moderate-to-severe plaque psoriasis, supported by established regulatory pathways.

•2mo ago

Can-Fite Launches First Clinical Program for Piclidenoson in the Rare Genetic Disease Lowe Syndrome

Can-Fite submitted a Phase 2 clinical study protocol to Bambino Gesù Children's Hospital for Piclidenoson targeting Lowe syndrome, a rare genetic disorder with no approved therapies. The open-label pilot study will enroll five adult patients for six months of twice-daily oral dosing, focusing on renal uptake as the primary endpoint. The program is supported by a collaboration with Fondazione Telethon and builds on preclinical data demonstrating restoration of OCRL-dependent cellular function.

•2mo ago

Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology

Can-Fite BioPharma announced that its Phase 2a study of Namodenoson in advanced pancreatic cancer has been accepted for poster presentation at the ESMO Congress 2026. The study demonstrated durable disease stabilization and survival outcomes, including one second-line patient remaining alive for more than 18 months. Based on these findings, the company is planning a Phase 2b study to evaluate Namodenoson in combination with chemotherapy.

•3mo ago

Can-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancer

Can-Fite BioPharma announced that the Australian Patent Office has allowed a patent application for Namodenoson covering the treatment of advanced metastatic cancer. The patent strengthens the company's global intellectual property portfolio for its lead drug, which is currently in a pivotal Phase 3 trial for advanced hepatocellular carcinoma and a planned Phase 2b study for pancreatic cancer. Management highlighted that this allowance extends protection for the therapeutic approach in a major international market, reinforcing the long-term value of the oncology franchise.

•3mo ago

Can-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027

Can-Fite BioPharma completed enrolment of 247 patients for the interim analysis of its pivotal Phase 3 study evaluating Piclidenoson for moderate-to-severe plaque psoriasis. The interim analysis is conducted under a protocol agreed with the FDA and EMA, with data expected in Q4 2026 or Q1 2027. Piclidenoson is a first-in-class oral A3AR agonist targeting key inflammatory pathways, offering a potential oral alternative to injectable biologics.

•3mo ago

Can-Fite Phase 2a Pancreatic Cancer Study with Namodenoson Achieves Primary Safety Endpoint and Demonstrates Durable Survival Outcomes in Advanced Disease

Can-Fite BioPharma reported positive results from its Phase 2a study of Namodenoson in advanced pancreatic cancer, achieving the primary safety endpoint and demonstrating durable overall survival in heavily pretreated patients. In the evaluable third-line population, median overall survival exceeded five months, with 62.5% of patients surviving at least five months and one second-line patient remaining alive for more than 18 months. Based on these findings and preclinical data showing enhanced chemosensitivity, the company plans to advance Namodenoson into a Phase 2b combination study with chemotherapy.

•4mo ago

Can-Fite Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity Technology

Can-Fite BioPharma received a patent allowance from the Japan Patent Office covering the use of Namodenoson for inducing fat loss and treating obesity. This allowance strengthens the company's global intellectual property portfolio for the drug candidate, which already has secured protection in the U.S., Canada, Australia, and Israel. Management noted that the expanding patent estate supports Namodenoson's value as an oral therapeutic candidate in an obesity market projected to exceed $60 billion by 2030.

•4mo ago

Can-Fite Publishes Peer-Reviewed Scientific Article Demonstrating the Broad Therapeutic Potential of Piclidenoson and Namodenoson

Can-Fite announced the publication of a peer-reviewed article in Biomolecules Journal validating the broad therapeutic potential of its lead candidates, Piclidenoson and Namodenoson. The review highlights evidence of A3AR agonist activity in treating diverse conditions including solid tumors, MASH, Alzheimer's disease, and osteoarthritis. Current pipeline status includes Namodenoson in Phase 3 for hepatocellular carcinoma and Phase 2 for pancreatic cancer and MASH, while Piclidenoson is in a pivotal Phase 3 study for psoriasis.

•4mo ago

Can-Fite Reports Positive Clinical Observation in Phase 2a Pancreatic Cancer Study and Highlights Namodenoson’s RAS Signaling Inhibition Mechanism

Can-Fite highlighted encouraging clinical observations from its Phase 2a study of namodenoson in pancreatic cancer, noting that enrollment is complete. Several patients demonstrated prolonged disease control, with one patient remaining on therapy and follow-up for approximately 16 months. The company emphasized namodenoson’s differentiated mechanism, which simultaneously targets RAS, Wnt/β-catenin, and NF-κB signaling pathways, aligning with growing clinical validation of RAS inhibition at ASCO.

•4mo ago

Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market

Can-Fite announced the publication of a peer-reviewed article in Frontiers in Veterinary Science validating Piclidenoson for canine osteoarthritis. The study showed statistically significant improvements in mobility, pain scores, and lameness in dogs treated with Piclidenoson, with a favorable safety profile. Piclidenoson is being developed for veterinary use by partner Vetbiolix under a licensing agreement potentially worth up to $325 million in upfront, milestone, and royalty payments.

•5mo ago

Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy

Can-Fite BioPharma is advancing its pancreatic cancer program into a Phase 2b study, evaluating Namodenoson in combination with immunotherapy. The decision follows positive Phase 2a data, which showed a favorable safety profile and clinical activity, including prolonged treatment duration and stable disease in over 30% of evaluable patients. Details of the Phase 2b study design will be discussed at the upcoming BIO International Convention in San Diego, where Can-Fite is meeting with leading oncology companies to explore partnership opportunities. Namodenoson has received Orphan Drug Designation from the FDA for the treatment of pancreatic cancer, highlighting its potential in this deadly disease.

•5mo ago